Member area login
You don't have or don't remember the password!
Click Here
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282


ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da E.M. Biganzoli

Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review
<p>Human epididymis protein 4 (HE4) measurements in serum have been proposed for improving the specificity of&nbsp;laboratory identification of ovarian cancer (OC). This study sought to critically revise the available literature on the&nbsp;comparison between the diagnostic accuracy of HE4 and carbohydrate antigen 125 (CA-125) to provide evidence of&nbsp;HE4 additional clinical value. Literature search was undertaken on electronic databases and references from&nbsp;retrieved articles, and articles analyzed according to predefined criteria. Meta-analyses for HE4 and CA-125&nbsp;biomarkers with odds ratio (OR), diagnostic sensitivity, specificity, positive (LR+) and negative (LR&ndash;) likelihood ratios&nbsp;as effect sizes were performed. Sixteen articles were originally included in meta-analyses, but two for HE4 and one&nbsp;for CA-125 were eliminated as outliers. Furthermore, for HE4 a publication bias was detected. ORs for both HE4&nbsp;(37.2, 95% CI: 19.0-72.7, adjusted for publication bias) and CA-125 (15.4, 95% CI: 10.4-22.8) were significant,&nbsp;although in a heterogeneous set of studies (P &lt;0.0001). By combining sensitivity and specificity, the overall LR+ and&nbsp;LR&ndash; were 13.0 (95% CI: 8.2-20.7) and 0.23 (95% CI: 0.19-0.28) for HE4 and 4.2 (95% CI: 3.1-5.6) and 0.27 (95% CI:&nbsp;0.23-0.31) for CA-125, respectively. HE4 measurement seems to be superior to CA-125 in terms of diagnostic&nbsp;performance for identification of OC in women with suspected gynecological disease. Due to the high prevalence of&nbsp;OC in post-menopausal women and the need of data focused on early tumor stages, more studies tailored on these&nbsp;specific subsets are needed.</p>
Biochimica Clinica ; 37(3) 179-189
Rassegne - Reviews